RECRUITINGPhase 1INTERVENTIONAL
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-272 in Healthy Subjects
About This Trial
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272.
Who May Be Eligible (Plain English)
Key Who May Qualify:
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
- A total body weight of more than (\>) 50 kg
- Male and Female participants of non-childbearing potential
Key Who Should NOT Join This Trial:
- History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
- Any condition possibly affecting drug absorption
Other protocol defined Inclusion/Exclusion criteria may apply.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Key Inclusion Criteria:
* Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
* A total body weight of more than (\>) 50 kg
* Male and Female participants of non-childbearing potential
Key Exclusion Criteria:
* History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
* Any condition possibly affecting drug absorption
Other protocol defined Inclusion/Exclusion criteria may apply.
Treatments Being Tested
DRUG
VX-272
Suspension for Oral Administration.
DRUG
Placebo
Suspension for Oral Administration.
Locations (1)
Celerion - Tempe
Tempe, Arizona, United States